TY  - JOUR
AU  - Horne, HN
AU  - Oh, H
AU  - Sherman, ME
AU  - Palakal, M
AU  - Hewitt, SM
AU  - Schmidt, MK
AU  - Milne, RL
AU  - Hardisson, D
AU  - Benitez, J
AU  - Blomqvist, C
AU  - Bolla, MK
AU  - Brenner, H
AU  - Chang-Claude, J
AU  - Cora, R
AU  - Couch, FJ
AU  - Cuk, K
AU  - Devilee, P
AU  - Easton, DF
AU  - Eccles, DM
AU  - Eilber, U
AU  - Hartikainen, JM
AU  - Heikkila, P
AU  - Holleczek, B
AU  - Hooning, MJ
AU  - Jones, M
AU  - Keeman, R
AU  - Mannermaa, A
AU  - Martens, JWM
AU  - Muranen, TA
AU  - Nevanlinna, H
AU  - Olson, JE
AU  - Orr, N
AU  - Perez, JIA
AU  - Pharoah, PDP
AU  - Ruddy, KJ
AU  - Saum, K-U
AU  - Schoemaker, MJ
AU  - Seynaeve, C
AU  - Sironen, R
AU  - Smit, VTHBM
AU  - Swerdlow, AJ
AU  - Tengstrom, M
AU  - Thomas, AS
AU  - Timmermans, AM
AU  - Tollenaar, RAEM
AU  - Troester, MA
AU  - van Asperen, CJ
AU  - van Deurzen, CHM
AU  - Van Leeuwen, FF
AU  - Van'tVeer, LJ
AU  - Garcia-Closas, M
AU  - Figueroa, JD
Y2  - 2020/12/10
Y1  - 2018/04/26
SN  - 2045-2322
UR  - http://hdl.handle.net/11343/253723
AB  - E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
LA  - English
PB  - NATURE PUBLISHING GROUP
T1  - E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium
DO  - 10.1038/s41598-018-23733-4
IS  - Scientific Reports
VL  - 8
IS  - 1
L1  - /bitstream/handle/11343/253723/PMC5920115.pdf?sequence=1&isAllowed=y
ER  -